

**EVIDENCE FOR TECHNICAL UPDATE  
OF POCKET BOOK RECOMMENDATIONS**

# **Recommendations for management of common childhood conditions**

**Newborn conditions, dysentery,  
pneumonia, oxygen use and  
delivery, common causes of  
fever, severe acute malnutrition  
and supportive care**



**World Health  
Organization**



EVIDENCE FOR TECHNICAL UPDATE  
OF POCKET BOOK RECOMMENDATIONS

---

# **Recommendations for management of common childhood conditions**

Newborn conditions, dysentery,  
pneumonia, oxygen use and delivery,  
common causes of fever,  
severe acute malnutrition and  
supportive care



**World Health  
Organization**

## WHO Library Cataloguing-in-Publication Data

---

Recommendations for management of common childhood conditions: evidence for technical update of pocket book recommendations: newborn conditions, dysentery, pneumonia, oxygen use and delivery, common causes of fever, severe acute malnutrition and supportive care.

1.Child care. 2.Pediatrics. 3.Disease management. 4.Child, Hospitalized. 5.Practice guidelines. I.World Health Organization.

ISBN 978 92 4 150282 5

(NLM classification: WS 29)

## © World Health Organization 2012

---

All rights reserved. Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site ([http://www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Designed by minimum graphics  
Printed in Switzerland

---

# Contents

Acronyms and abbreviations	ix
Acknowledgement	xi
<b>Executive summary</b>	<b>1</b>
<b>1. Introduction</b>	<b>3</b>
1.1 Target audience	4
1.2 Objectives of the recommendations	4
1.3 Financial support	4
1.4 Management of conflict of interest	4
1.5 Guiding principles	5
<b>2. Methodology and process</b>	<b>6</b>
2.1 Defining the scope	6
2.2 Evidence retrieval and synthesis process	7
2.3 Consensus building and external peer review	8
2.4 Review and update of the recommendations	9
<b>3. Implementation of the recommendations</b>	<b>10</b>
3.1 Proposed subsidiary products	10
3.2 Implementation of the recommendations	11
3.3 National adaptation and implementation	11
<b>4. Recommendations</b>	<b>13</b>
4.1 Vitamin K prophylaxis in newborns	13
4.2 Prophylactic antibiotics in newborns with risk factors for infection	13
4.3 Skin-to-skin contact in the first hour of life	13
4.4 Management of neonatal jaundice	14
4.5 Empirical antibiotics for suspected neonatal sepsis	14
4.6 Head or whole body cooling in management of hypoxic ischaemic encephalopathy	15
4.7 Antibiotics for treatment of necrotizing enterocolitis	15
4.8 Kangaroo Mother Care	15

4.9	Prevention of hypothermia immediately after birth in LBW infants	15
4.10	Treatment of non-severe pneumonia with wheeze	15
4.11	Antibiotic treatment for non-severe pneumonia with no wheeze	15
4.12	Antibiotics treatment for severe pneumonia	16
4.13	Antibiotic treatment for very severe pneumonia	16
4.14	Inhaled salbutamol for treatment of acute wheeze/asthma and bronchoconstriction	16
4.15	Antibiotics for treatment of dysentery	17
4.16	Antibiotics for treatment of acute bacterial meningitis	17
4.17	Antibiotics for treatment of acute otitis media	17
4.18	Topical antibiotics for treatment of chronic suppurative otitis media (CSOM)	18
4.19	Topical antiseptics for treatment of chronic suppurative otitis media	18
4.20	Topical steroids for treatment of chronic suppurative otitis media	18
4.21	Antibiotics for treatment of typhoid fever	18
4.22	Antibiotics in management of severe acute malnutrition (SAM)	19
4.23	Pulse oximetry for detection of hypoxaemia	19
4.24	Clinical signs for detection of hypoxaemia in children	19
4.25	Oxygen therapy in treatment of hypoxaemia	20
4.26	Thresholds for administering oxygen therapy	20
4.27	Oxygen delivery methods	20
4.28	Criteria for starting and stopping oxygen therapy	20
4.29	Sublingual administration of sugar in the treatment of hypoglycaemia	21
4.30	Choice of intravenous fluids for resuscitation and maintenance in children	21
<b>5.</b>	<b>Evidence for recommendations on the newborn conditions</b>	<b>22</b>
5.1	Vitamin K prophylaxis in newborns	22
5.1.1	Evidence and summary of findings	22
5.1.2	Benefits and risks	23
5.1.3	Acceptability and feasibility	23
5.2	Prophylactic antibiotics in newborns at risk of infection	23
5.2.1	Evidence and summary of findings	24
5.2.2	Benefits and risks	24
5.2.3	Acceptability and feasibility	24
5.3	Skin-to-skin contact in the first hour of life	24
5.3.1	Evidence and summary of findings	25
5.3.2	Benefits and risks	25
5.3.3	Acceptability and feasibility	26
5.4	Management of neonatal jaundice	26
5.4.1	Evidence and summary of findings	27

5.4.2	Benefits and risks	27
5.4.3	Acceptability and feasibility	27
5.5	Empirical antibiotics for suspected neonatal sepsis	28
5.5.1	Evidence and summary of findings	28
5.5.2	Benefits and risks	29
5.5.3	Acceptability and feasibility	29
5.6	Head or whole body cooling in management of hypoxic ischaemic encephalopathy	29
5.6.1	Evidence and summary of findings	29
5.6.2	Benefits and risks	30
5.6.3	Acceptability and feasibility	30
5.7	Antibiotics for treatment of necrotizing enterocolitis	31
5.7.1	Evidence and summary of findings	31
5.7.2	Benefits and risks	32
5.7.3	Acceptability and feasibility	32
5.8	Kangaroo Mother Care	32
5.8.1	Evidence and summary of recommendations	32
5.8.2	Benefits and risks	33
5.8.3	Acceptability and feasibility	33
5.9	Prevention of hypothermia immediately after birth in low birth weight infants	34
5.9.1	Evidence and summary of findings	34
5.9.2	Benefits and risks	35
5.9.3	Acceptability and feasibility	35
<b>6.</b>	<b>Evidence for recommendations for treatment of pneumonia</b>	<b>36</b>
6.1	Antibiotic treatment for non-severe pneumonia with wheeze	36
6.1.1	Evidence and summary of findings	36
6.1.2	Benefits and risks	39
6.1.3	Acceptability and feasibility	39
6.2	Antibiotic treatment for non-severe pneumonia with no wheeze	40
6.2.1	Evidence and summary of findings	40
6.2.2	Benefits and risks	42
6.2.3	Acceptability and feasibility	42
6.3	Antibiotics treatment for severe pneumonia	42
6.3.1	Evidence and summary of findings	42
6.3.2	Benefits and risks	44
6.3.3	Acceptability and feasibility	44
6.4	Antibiotics treatment for very severe pneumonia	44
6.4.1	Evidence and summary of findings	45

6.4.2	Benefits and risks	46
6.4.3	Acceptability and feasibility	46
6.5	Salbutamol for treatment of acute wheeze/asthma and bronchoconstriction	46
6.5.1	Evidence and summary of findings	46
6.5.2	Benefits and risks	46
6.5.3	Acceptability and feasibility	47
<b>7.</b>	<b>Evidence for recommendations for treatment of dysentery</b>	<b>48</b>
7.1	Antibiotics for treatment of dysentery	48
7.1.1	Evidence and summary of findings	48
7.1.2	Benefits and risks	50
7.1.3	Acceptability and feasibility:	50
<b>8.</b>	<b>Evidence for recommendations on treatment of fever conditions</b>	<b>52</b>
8.1	Antibiotics for treatment of acute bacterial meningitis	52
8.1.1	Evidence and summary of findings	53
8.1.2	Benefits and risks	54
8.1.3	Acceptability and feasibility	55
8.2	Antibiotic treatment for acute otitis media (AOM)	55
8.2.1	Evidence and summary of findings	56
8.2.2	Benefits and risks	57
8.2.3	Acceptability and feasibility	58
8.3	Antibiotic treatment for chronic suppurative otitis media (CSOM)	58
8.3.1	Evidence and summary of findings	58
8.3.2	Benefits and risks	59
8.3.3	Acceptability and feasibility	59
8.4	Topical antiseptics for treatment of chronic suppurative otitis media (CSOM)	59
8.4.1	Evidence and summary of findings	59
8.4.2	Benefits and risks	60

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_28595](https://www.yunbaogao.cn/report/index/report?reportId=5_28595)

